Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

By sjmartinez • January 25, 2025

Krishnan S, Srivastava PK, Attaluri J, Nayeri R, Chatterjee D, Patel J, Nsair A, Budoff M, Nayeri A. Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence. J Cardiovasc Dev Dis. 2025 Jan 7;12(1):19. doi: 10.3390/jcdd12010019. PMID: 39852297; PMCID: PMC11766028.

Tags: Cardiology/Epi, GIP GLP-1 receptor agonist, Harbor UCLA, Hematology/Oncology, Metabolic syndrome, Obesity, Publications, semaglutide, tirzepatide, Veterans Administration, weight loss

Refractive Index-Corrected Light-Sheet Microscopy for Macro-View Cardiovascular Imaging

Zhu E, Zhang Y, Zhao P, Cho JM, Wang Z, Li YR, Wang J, Margolis S, Wang S, Yang L, Chu A, Zhang Y, Gao[...]

Bisphosphonate Use and Cardiovascular Outcomes According to Kidney Function Status in Post-Menopausal Women: An Emulated Target Trial from the Multi-Ethnic Study of Atherosclerosis

Ghotbi E, Subhas N, Bancks MP, Elmariah S, Halperin JL, Bluemke DA, Kestenbaum BR, Barr RG, Post WS, Budoff M, Lima JAC, Demehri S. Bisphosphonate[...]

Acute Cardiogenic Shock Secondary to Left Main Occlusion in a Patient with Behçet Disease

Sekhon HK, Sareh S, Kellner D, Yiu G, Benharash P, Hollowed J, Shahandeh N. Acute Cardiogenic Shock Secondary to Left Main Occlusion in a Patient[...]